This country profile provides an overview of Mozambique’s progress in reaching those in need of mass NTD treatment based on 2017 data.

*This includes all countries in Africa that are endemic for at least one of the five NTDs

Download country profiles

Treatment coverage

Elephantiasis
80%
Blinding trachoma
0%
Intestinal worms
87%
Bilharzia
32%
River blindness
NA
19.08 million people received treatment in Mozambique in 2017 4.37 million people did not receive treatment in Mozambique in 2017

Priorities for progress in Mozambique

  • Mozambique is commended for the leadership demonstrated by the Government, with the recent announcement by the Prime Minister of US$6M in domestic resources for NTDs.
  • With these resources, Mozambique is encouraged to work to clarify the epidemiology of river blindness in the country.
  • Further, it should work to identify the reasons for the fluctuating coverage rates for bilharzia, intestinal worms and trachoma and systematically work to address the issues identified.
  • Support the Expanded Special Project for Elimination of Neglected Tropical Diseases (ESPEN) established by WHO AFRO region for the elimination of these five diseases.

Elephantiasis

Treatment coverage increased from 74% in 2016 to 80% in 2017.

People needing treatment
19.76m
People receiving treatment
15.8m

Blinding trachoma

Treatment coverage decreased from 45% in 2016 to 0% in 2017.

People needing treatment
4.4m
People receiving treatment
0m

Intestinal worms

Treatment coverage increased from 57% in 2016 to 87% in 2017.

Pre-sch and school-aged children needing treatment
11.73m
Pre-school and school-aged children receiving treatment
10.24m

Bilharzia

Treatment coverage decreased from 93% in 2016 to 32% in 2017.

School-aged children needing treatment
5.67m
School-aged children receiving treatment
1.78m

River blindness

Mozambique does not require mass treatment for river blindness.

The ESPEN portal (a World Health Organization AFRO region project) provides maps and district-level data for the preventive chemotherapy diseases in Mozambique.